skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Varenicline for smoking cessation: efficacy, safety, and treatment recommendations

Review

(2053) Views  (578) Full article downloads

Authors: Jon O Ebbert, Kirk D Wyatt, J Taylor Hays, et al

Published Date September 2010 Volume 2010:4 Pages 355 - 362
DOI: http://dx.doi.org/10.2147/PPA.S10620

Jon O Ebbert, Kirk D Wyatt, J Taylor Hays, Eric W Klee, Richard D Hurt
Mayo Clinic College of Medicine, Rochester, MN, USA

Abstract: Smoking is the leading preventable cause of morbidity and mortality in the US, and decreasing smoking prevalence is a public health priority. Patients achieve the greatest success when quit attempts involve behavioral therapy combined with pharmacotherapy. Varenicline is the most recent addition to the pharmacotherapeutic armamentarium for the treatment of tobacco dependence. Varenicline is efficacious and cost-effective. Smoking relapse and adverse treatment-related side effects may decrease medication adherence and patient satisfaction with varenicline. In the clinical setting, varenicline treatment can be optimized by reducing doses in patients who experience intolerable side effects, increasing the dose in partial responders, and providing long-term maintenance therapy for relapse prevention.

Keywords: varenicline, tobacco dependence, smoking cessation, nicotine addiction




 

Other articles by Dr Jon Ebbert



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options
Exploring patients’ perceptions for insulin therapy in type 2 diabetes: a Brazilian and Canadian qualitative study
The utility of an electronic adherence assessment device in type 2 diabetes mellitus: a pilot study of single medication
Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence
Racial differences in diabetes-related psychosocial factors and glycemic control in patients with type 2 diabetes
Measuring nutritional risk in hospitals
Impact of depression and social support on nonadherence to antipsychotic drugs in persons with schizophrenia in Thailand
A systematic writing program as a tool in the grief process: part 1
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy